UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management

The oncologist (Dayton, Ohio), 2020-04, Vol.25 (4), p.290-300

2020

Volltextzugriff (PDF)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001395

2020

Volltextzugriff (PDF)

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

Frontiers in oncology, 2021-03, Vol.10, p.581801-581801

2021

Volltextzugriff (PDF)

Relugolix in Clinical Practice: The Best Route for All?

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (8), p.647-650

2023

Volltextzugriff (PDF)

The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?

The lancet oncology, 2021-07, Vol.22 (7), p.915-916

2021

Volltextzugriff (PDF)

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

The Lancet (British edition), 2022-08, Vol.400 (10351), p.512-521

2022

Volltextzugriff (PDF)

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

The oncologist (Dayton, Ohio), 2020-06, Vol.25 (6), p.479-e899

2020

Volltextzugriff (PDF)

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

Clinical cancer research, 2019-08, Vol.25 (16), p.4933-4944

2019

Volltextzugriff (PDF)

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity

European urology oncology, 2024-10, Vol.7 (5), p.971-972

2024

Volltextzugriff (PDF)

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute

Journal of clinical oncology, 2022-06, Vol.40 (17), p.1949-1957

2022

Volltextzugriff (PDF)

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

The oncologist (Dayton, Ohio), 2022-09, Vol.27 (9), p.718-e694

2022

Volltextzugriff (PDF)

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

Clinical cancer research, 2021-01, Vol.27 (2), p.429-437

2021

Volltextzugriff (PDF)

Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids

JAAD Case Reports, 2017-07, Vol.3 (4), p.322-325

2017

Volltextzugriff (PDF)

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single‐Dose Administration Under Fasting Conditions in Prostate Cancer

The oncologist (Dayton, Ohio), 2021-09, Vol.26 (9), p.729-e1493

2021

Volltextzugriff (PDF)

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Cancer chemotherapy and pharmacology, 2020-10, Vol.86 (4), p.475-486

2020

Volltextzugriff (PDF)

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment

Clinical genitourinary cancer, 2020-08, Vol.18 (4), p.258-267.e1

2020

Volltextzugriff (PDF)

Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide

European urology oncology, 2024-08, Vol.7 (4), p.735-741

2024

Volltextzugriff (PDF)

Construire un « je » genré dans les traductions de Catulle (c. 51 et 66) : Érotique de l’appropriation littéraire et féminisation rétrospective des modèles grecs

The Gendered 'I' in Ancient Literature, 2022, Vol.18

2022

Volltextzugriff (PDF)

Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.116-116

2023

Volltextzugriff (PDF)

Association of 18 F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4600-4600

2023

Volltextzugriff (PDF)

Phase 2 study of bintrafusp alfa in recurrent/metastatic olfactory neuroblastoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS6116-TPS6116

2023

Volltextzugriff (PDF)

Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2628-2628

2023

Volltextzugriff (PDF)

A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5101-TPS5101

2023

Volltextzugriff (PDF)

1 – 25 von 129

Suche als RSS-Feed

Aktive Filter

ThemaImmunotherapy

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)

Publikationsform

Sprache

Englisch
(129)

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Life Sciences & Biomedicine
(41)
Humans
(26)
Oncology
(23)
Male
(14)
Female
(12)
Middle Aged
(10)
Aged
(7)
Prostate Cancer
(7)
Multidisciplinary Sciences
(6)
Science & Technology - Other Topics
(6)
Urology & Nephrology
(6)
Adult
(5)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)
Cancer
(5)
Aged, 80 And Over
(4)
Animals
(4)
Biodiversity
(4)
Clinical Trial Results
(4)
Deep Sea
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

Relugolix in Clinical Practice: The Best Route for All?

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single‐Dose Administration Under Fasting Conditions in Prostate Cancer

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment

Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide

Construire un « je » genré dans les traductions de Catulle (c. 51 et 66) : Érotique de l’appropriation littéraire et féminisation rétrospective des modèles grecs

Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers

Association of 18 F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies

Phase 2 study of bintrafusp alfa in recurrent/metastatic olfactory neuroblastoma

Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C)

A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL)

Aktive Filter

Suchergebnisse filtern